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Cerebrovascular dysfunction and cerebral amyloid angiopathy (CAA) are hallmark
features of Alzheimer’s disease (AD). Molecular damage to cerebrovessels in AD may
result in alterations in vascular clearance mechanisms leading to amyloid deposition
around blood vessels and diminished neurovascular-coupling. The sequelae of molecular
events leading to these early pathogenic changes remains elusive. To address this,
we conducted a comprehensive in-depth molecular characterization of the proteomic
changes in enriched cerebrovessel fractions isolated from the inferior frontal gyrus of
autopsy AD cases with low (85.5 ± 2.9 yrs) vs. high (81 ± 4.4 yrs) CAA score,
aged-matched control (87.4 ± 1.5 yrs) and young healthy control (47 ± 3.3 yrs)
cases. We employed a 10-plex tandem isobaric mass tag approach in combination
with our ultra-high pressure liquid chromatography MS/MS (Q-Exactive) method.
Enriched cerebrovascular fractions showed very high expression levels of proteins
specific to endothelial cells, mural cells (pericytes and smooth muscle cells), and
astrocytes. We observed 150 significantly regulated proteins in young vs. aged
control cerebrovessels. The top pathways significantly modulated with aging included
chemokine, reelin, HIF1α and synaptogenesis signaling pathways. There were 213
proteins significantly regulated in aged-matched control vs. high CAA cerebrovessels.
The top three pathways significantly altered from this comparison were oxidative
phosphorylation, Sirtuin signaling pathway and TCA cycle II. Comparison between
low vs. high CAA cerebrovessels identified 84 significantly regulated proteins. Top
three pathways significantly altered between low vs. high CAA cerebrovessels included
TCA Cycle II, Oxidative phosphorylation and mitochondrial dysfunction. Notably, high
CAA cases included more advanced AD pathology thus cerebrovascular effects
may be driven by the severity of amyloid and Tangle pathology. These descriptive
proteomic changes provide novel insights to explain the age-related and AD-related
cerebrovascular changes contributing to AD pathogenesis. Particularly, disturbances in
energy bioenergetics andmitochondrial biology rank among the top AD pathways altered
in cerebrovessels. Targeting these failed mechanisms in endothelia and mural cells may
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provide novel disease modifying targets for developing therapeutic strategies against
cerebrovascular deterioration and promoting cerebral perfusion in AD. Our future work
will focus on interrogating and validating these novel targets and pathways and their
functional significance.
Keywords: cerebrovasculature, Alzheimers disease, cerebral amyloid angiopathy, endothelial cells, mural cells,
proteomics, mass spectrometry, perivascular cells
INTRODUCTION
Alzheimer’s disease (AD) is a chronic age-related
neurodegenerative disorder and the predominant type
of dementia, marked by deposits of amyloid plaques and
neurofibrillary tangles composed of hyperphosphorylated tau
(Holtzman et al., 2012). To date AD remains untreatable, with
very few disease modifying therapeutic approaches advancing
into human clinical trials. There is thus an urgent need to identify
new biological perspectives behind the neurological dysfunction
and underlying etiology of AD.
One of the most common pathological features of AD
is vascular dysfunction (De La Torre, 2010). Neuroimaging
abnormalities have demonstrated early preclinical features such
as cerebral perfusion and metabolic deficits (De la Torre
and Mussivand, 1993; de la Torre, 2018), and diminished
cortical blood flow beginning many years prior to the onset of
neurological symptoms (Binnewijzend et al., 2016; Hays et al.,
2016). One of the most common vascular associated lesions
in AD is cerebral amyloid angiopathy (CAA), typified by the
accumulation of Aβ in leptomeninges and along cerebral blood
vessels. Seminal findings from the Nun study also reported
lacunar infarcts as a prominent vascular lesion that reduces the
neuropathological threshold required for defining the staging
of AD neuropathology (Snowdon, 1997). Similar large cohort
aging studies have likewise confirmed the presence of underlying
cerebrovascular abnormalities such as cerebrovascular small
vessel disease (CSVD) lesions as a strong predictor of clinical
presentation or cognitive deficits in AD patients (Nagy et al.,
1997). Moreover, vascular dementia and AD related dementia
both share a significant degree of overlap in their clinical and
neuropathological profiles (Kalaria and Ballard, 1999; Kalaria,
2003; Erkinjuntti et al., 2004; Custodio et al., 2017).
At autopsy, other vascular associated morphological lesions
can be observed in aging and AD brains such as degeneration
of arterioles and leptomeningeal vessels (Vinters et al., 1994;
Kalaria, 1996; Farkas and Luiten, 2001), capillaries and mural
cells (Miyakawa and Kuramoto, 1989; Hashimura et al.,
1991; Kimura et al., 1991; Farkas et al., 2000; Østergaard
et al., 2013); mitochondria abnormalities and deposition
of phagolysosomes and lipofuscin in cerebrovascular cells
(Miyakawa and Kuramoto, 1989); degeneration of the blood
brain barrier (Deane and Zlokovic, 2007), arteriolar wall
thickening or arteriolosclerosis (Neltner et al., 2014; Blevins et al.,
2021), propensity for plaque build up in cerebral arteries(Roher
et al., 2004; Beach et al., 2007; Yarchoan et al., 2012), immune
cell recruitment and influx of blood borne proteins (Itagaki et al.,
1988; Rogers et al., 1988; Togo et al., 2002; Grammas et al., 2006;
Di Marco et al., 2015; Merlini et al., 2018).
The consequences of these early vascular changes may
significantly impact amyloid clearance and ultimately neuronal
metabolism and cerebral brain function (Mosconi, 2005;
Mawuenyega et al., 2010). Likewise, amyloid deposition on
vascular walls can also induce changes contributing to narrowing
and weakening of the vascular wall leading to increased
cerebral blood pressure (Kalback et al., 2004; Tian et al., 2004).
Whether vascular dysfunction is a prelude to AD pathogenesis
or a consequence remains elusive (Govindpani et al., 2019).
Understanding the molecular response of the cerebrovasculature
during the sequelae of normal aging and AD pathogenesis may
provide clues as to the etiology of vascular dysfunction in AD.
Advances in omic approaches has enabled interrogation of
different brain regions of AD cases across the neuropathological
staging of the disease and age matched healthy controls (Johnson
et al., 2018, 2020; Bai et al., 2020). Unbiased proteomic analysis is
an extremely powerful tool which can provide a very expansive
interrogation of the molecular response in neurodegenerative
diseases and can lead to identification of pathogenic mechanisms
and novel molecular targets for therapeutic exploration (Zhang
et al., 2008). However, very few studies have explored the
molecular integrity of the cerebrovasculature in aging and AD.
To address this, we will use our state-of-the-art unbiased
proteomic (mass spectrometry) based platform to conduct a
detailed characterization and assessment of molecular changes in
protein expression levels, cellular origin of proteomic changes,
molecular pathways and biofunctions significantly altered in the
cerebrovasculature isolated from AD patients compared to aged
matched control cases. To further understand the contribution of
age, we will also interrogate cases from young (40-50’s) compared
to aged (70’s-90’s) control cases.
We utilize a novel protein extraction protocol, separating
isolated cerebrovascular samples into cytosolic, membrane and
nuclear fractions to increase the depth of the protein mining
process, and coupled this with a 10-plex tandem isobaric mass
tag (TMT) approach for interrogation with an ultra-high pressure
liquid chromatography MS/MS (Q-Exactive) method. We detail
the unique and common molecular profiles and pathogenic
mechanisms driving cerebrovascular changes in the inferior
frontal gyrus of young vs. aged brains, and CAA staged AD vs.
age-matched control cases.
METHODS
Human Tissue and Patient Demographics
Frozen human cortex tissue samples (from the inferior frontal
gyrus) were provided mainly from Dr. Thomas Beach, Director
of the Brain and Body Donation Program at Sun Health Research
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Institute (Sun City, AZ) in accordance with the institutional
bioethics guidelines. Additional samples were requested from
the NIH BrainBank repository (University of Maryland and
Ican school of medicine, Mount Sinai, NY). The donors
and their respective families provided hand written informed
consent for autopsy and the subsequent use of brain tissue for
research purposes. For this study, no further ethical approval
was required as samples were obtained from deceased, de-
identified, and consenting individuals. Neuropathological post-
mortem diagnosis of AD (i.e., amyloid plaque and Tangle
pathology) was determined using the Consortium to Establish
a Registry for Alzheimer’s Disease (CERAD) diagnostic criteria
and the consensus recommendation by the National Institute for
Aging/Reagan Institute Working Group. Braak staging was used
to characterize the geographic spread of neurofibrillary tangle
pathology (NFT). The severity of CAA was performed according
to Vonsattel et al. (1991), and the stage of topographical
expansion of CAA was assessed as previously described by Thal
et al. (2003) based on a four point numerical conversion per
region. Global scores for amyloid, tangle and CAA burden from
the microscopic lesion densities were calculated based on the
sums of the scores from all regions interrogated. A summary of
patient demographics, and clinical information of brain donors
used in this proteomic study is provided in Table 1.
Isolation of Enriched Cerebrovessel
Fractions
The enriched cerebrovasculature was isolated from the inferior
frontal gyrus brain tissue as previously characterized and
described by our group (Alonzo et al., 1998; Ojo et al., 2021).
Briefly, frozen blocks of brain tissue (500mg) from the inferior
frontal gyrus was homogenized in ice-cold Hanks Buffered salt
solution (HBBS) in a glass dounce homogenizer, using 6-8 passes
of a Teflon pestle tissue grinder. Forty percent dextran solution
was added to the brain homogenate at an equal volume in a 15ml
falcon tube, to generate a final concentration of 20% dextran,
which was subsequently centrifuged at 6,000 g for 15 mins at
4◦C. Three visible layers were produced in the 15ml falcon tube
after centrifugation; the top layer consisted of a compact mass
(i.e., paraenchyma fraction), the bottom layer consisted of a
tissue pellet (i.e., the cerebrovasculature fraction), and this was
separated by a middle layer of translucent dextran interface (i.e.,
non-cell associated soluble fraction). For subsequent analyses we
used the bottom layer consisting of the whole cerebrovascular
fraction, containing vessels of a variety of sizes (microvessels,
arterioles, etc.). This fraction is highly enriched in endothelial
andmural cells (i.e., pericytes and smoothmuscle cells) and other
perivascular cell types (e.g., astrocytes etc..).
Subcellular Protein Extraction From
Vascular Homogenates
Two hundred and fifty microliters of ice cold phosphate buffered
saline (PBS) was added to each cerebrovascular pellet, followed
by homogenization using a probe sonicator and subsequent
centrifugation at 20,000 g for 5 mins at 4◦C. Supernatant was
collected in a different Eppendorf tube to obtain the PBS-
fraction. Pelleted samples were re-suspended in 250 ul of ice
cold PBS containing 1M sodium chloride, further sonicated and
centrifuged at 20,000 g for 5 mins at 4◦C. Supernatant was
collected in a different Eppendorf tube and labeled as PBS-
high salt fraction. The precipitant was resuspended in 250 ul of
ice cold 20mM Triethylamonium bicarbonate (TEAB) and 2%
lithium dodecylsulphate anionic detergent, sonicated, and also
followed by centrifugation at 20,000 g for 5 mins at 4◦C. Final
supernatant was transferred to a new Eppendorf tube and labeled
as the membrane protein pellet fraction. PBS, PBS-high salt
and membrane fractions (i.e., cytosolic, nuclear and membrane
proteins) were used in the entire study to enhance the proteomic
mining process.
Trypsin Digestion
Twelve and a half microliters of 21x proteinase inhibitor cocktail
was added to 250 ul of the PBS, PBS-high salt and membrane
protein fractions, followed by BCA analyses to determine
protein concentration. For the PBS fraction, 30 ug protein
was added to 3x volume of acetone, and left to incubate at
−20◦C for 1 h. Following centrifugation at 14,000 g for 1.5 mins
at room temperature, pelleted samples were brought up in 2
0ul modified reduction alkylation buffer (MRAB) consisting of
20mM TEAB at pH 8, 1% w/v sodium deoxycholate (SDC),
1mM tris (2-carboxyethyl) phosphine (TCEP), and 2.5mM 2-
chloroacetamide (CAM). For the PBS-high salt fraction, 30u g
protein was added to 1 in 5 parts of 20% w/v Trichloroacetic
acid (TCA) and 3x volume of acetone, and left to incubate on
ice for 1 h. Following centrifugation at 14,000 g for 1.5 mins at
room temperature, pelleted samples were washed with 200 ul of
acetone and pelleted material brought up in 20 ul MRAB. For the
membrane protein pellet fraction, 30 ug protein was added to
20% of 100% w/v Trichloroacetic acid (TCA), and left to incubate
on ice for 1 h. Following centrifugation at 14,000 g for 1.5 mins
at room temperature, pelleted samples were also washed with
200 ul of acetone and pelleted material resolubilized in 20 ul
of MRAB. Validation of protein separation in all three protein
fractions was conducted using sypro-red and Coomassie staining
for total protein after polyacrylamide gel electrophoresis. Seven
and a half microliters of all three protein fractions underwent
trypsin digestion at a 1:100 enzymatic concentration. Firstly, re-
suspended samples in MRAB were incubated at 37◦C for 30min;
7.5 ul of prepared activated trypsin solution (Promega, WI,
USA) was added to re-suspended samples, and further incubated
overnight at 37◦C while shaking mildly. Digested samples were
stored at−80◦C prior to TMT labeling.
Tandem Mass Tag (TMT) Labeling Strategy
We used a multiplexed isobaric labeling approach to allow
for simultaneous identification and quantification of proteins
from multiple biological samples. A 10-plex TMT labeling kit
(ThermoScientific, NJ, USA) was used for analyses of protein
samples from AD/controls and Aged/Young and an aged-
matched control sample was used as a reference sample per plex
for normalization of data and as a reference point for the different
runs. This labeling strategy allowed for all different groups to
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TABLE 1 | List of control and Alzheimer’s disease cases, their demographics, clinical background, APOE genotype, neuropathological score, and randomization of























Low CAA (≤4) M 78 2/3 1.5 5.5 C3 0 5 B2 IV Intermediate 0 0
Low CAA (≤4) M 77 2/3 3 12.5 C3 1.5 10.5 B2 IV Intermediate 0 1
Low CAA (≤4) F 91 2/3 2.5 8 C3 0 5 B2 IV Intermediate 1 1
Low CAA (≤4) F 96 3/3 3 12.5 C2 1.16 9.66 B3 V High 0 0
Low CAA (≤4) F 84 3/3 3 14.5 C3 3 14.75 B3 VI High 0 2
Low CAA (≤4) F 86 3/4 3 13.5 C2 1.5 12.5 B3 V High 1 3
Low CAA (≤4) F 92 4/4 3 14.5 C3 3 15 B3 VI High 0 2
Low CAA (≤4) M 67 3/4 2.5 11 C3 3 14.5 B3 V High 1 3
Low CAA (≤4) F 88 3/4 2.5 11.75 C2 1 9 B2 IV Intermediate 1 4
Low CAA (≤4) F 96 3/3 3 13.75 C2 0.5 8 B2 IV Intermediate 1
High CAA (≥8) M 96 2/3 0.5 4 C3 0 7 B2 IV Intermediate 3 10
High CAA (≥8) M 89 2/3 3 12.5 C3 1.5 10 B3 V High 2 8
High CAA (≥8) F 88 4/4 2 13 C3 2 13 B3 VI High 3 12
High CAA (≥8) M 68 4/4 3 15 C3 3 15 B3 VI High 2 9
High CAA (≥8) F 93 4/4 3 14 C3 3 14.5 B3 VI High 2 9
High CAA (≥8) M 83 4/4 3 15 C3 3 15 B3 VI High 2 9
High CAA (≥8) 58 14.5 C3 14 B3 VI High 8
High CAA (≥8) 60 12.5 C3 15 B3 VI High 12
High CAA (≥8) 90 14 C3 14.5 B3 VI High 9
High CAA (≥8) F 85 3/3 3 14 C3 3 15 B3 VI High
Aged control F 83 2/3 2.5 10 C2 0 1.5 B1 II Criteria not met 2 8
Aged control M 80 2/2 0 4.5 C1 0 5 B2 III Criteria not met 0 0
Aged control F 87 2/3 1.5 4.5 C2 0 4.25 B2 III Criteria not met 0 0
Aged control M 97 2/3 0 0 C0 0 5 B2 III Criteria not met 0 0
Aged control F 91 2/3 0 0 C0 0 5 B2 III Criteria not met 0 0
Aged control M 85 3/3 0 0 C0 0 1 B1 I Criteria not met 0 0
Aged control M 92 3/3 1.5 8 C2 0 4.5 B2 III Criteria not met 3 11
Aged control M 89 3/3 0 0 C0 0 2 B1 II Criteria not met 0 0
Aged control M 81 3/3 0 0 C0 0 4.5 B2 III Criteria not met 0 0
Aged control M 80 3/3 0 0 C0 0 4 B2 III Criteria not met 1 6
Aged control F 88 3/4 0 0.25 C0 0 2 B1 II Criteria not met 0 0
Aged control M 97 3/4 0 0 C0 0 5 B2 III Criteria not met 0 0
Aged control M 87 3/4 2 8.25 C2 0 2.5 B2 III Criteria not met 0 0
Aged control F 80 0 0 C0 B2 III Criteria not met 0 0
Aged control F 94 0 0 C0 B2 III Criteria not met 0 0












TMT 10 PLEX LABELS
Young controls (N = 9) 56% (5/9) 47 ± 3.3 67% (6/9) N/A N/A N/A N/A −126, −127N, −128C
Aged controls (N = 15) 60% (9/15) 87.4 ± 1.5 20% (3/15) 28.1 ± 0.5 0% (0/15) 0% (0/15) 0% (0/15) −126, −127N, −127C*, −128N
Low CAA Score (≤4) [AD] (N = 10) 30% (3/10) 85.5 ± 2.9 40% (4/10) 16.7 ± 2.4 50% (5/10) 60% (6/10) 50% (5/10) −129C,−130N, −130C, −131
High CAA Score (≥8) [AD] (N = 10) 40% (4/10) 81 ± 4.4 60% (6/10) 14 ± 3.3 90% (9/10) 100% (10/10) 90% (9/10) −129N, −129C,−130N, −130C, −131
Cx, Cortex; ADNC, Alzheimer’s disease neuropathological change; NIA-R, National institute of Aging Regan Diagnosis of AD.
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be randomized and analyzed within the same batch. All samples
and isobaric label tags were handled blind to the experimenter.
Twenty microliter aliquots of each label (dissolved in 20 ul of
acetonitrile solution) were dried down in the speed vacuum and
re-suspended in 25mM TEAB made up in acetonitrile solution.
Re-suspended labels were subsequently added to 10 ul of dried
digested protein samples, and allowed to incubate for 1 h at room
temperature, after which 1 ul of formic acid solution was added to
stop the reaction. Labeled samples were pooled together in entire
batches and subsequently dried in the speed vacuum.
Sodium Deoxycholate (SDC) and
Tetraethylammonium Bromide (TEAB)
Clean Up
To remove traces of SDC and TEAB, protein samples were re-
suspended in 100 ul of 1% formic acid solution and centrifuged
at 15,000 rpm for 1min to allow separation into different phases.
Supernatants were collected in new Eppendorf tubes, and 200 ul
of ethyl acetate was added, and centrifuged at 15,000 rpmwith the
upper organic layer discarded. This process was repeated three
separate times, with the final lower phase taken to dryness in the
speed vacuum. The resultant dried samples were re-solubilized in
100 ul of 0.1% formic acid.
Purification and Concentration of Peptides
Prior to ultra-high pressure liquid chromatography (UHPLC),
single step desalting, concentration and purification of peptides
were conducted using 0.6ul C18 resin Ziptips (ThermoScientific,
NJ, USA). Briefly, ziptips pipette tips were used to remove
contaminants by aspirating and dispensing in a solution of 0.1%
formic acid made up in 50% acetonitrile (i.e., wetting buffer), and
afterwards in a solution containing 0.1% formic acid (i.e., binding
buffer). Ziptips were used for sample binding, by aspirating and
dispensing through the samples multiple times. The resultant
concentrated and purified labeled samples were aspirated in a
solution of 5% methanol and 0.1% formic acid (i.e., washing
buffer), followed by elution in a solvent containing 10 ul of 0.1%
formic acid made up in 50% acetonitrile (wetting buffer). After
desalting and concentrating peptides, final samples were dried
and re-suspended in 20 ul of 0.1% formic acid and subsequently
transferred into an auto-sampler vial, and analyzed by nano-
Ultra-Performance Liquid Chromatography (UPLC) MS on a
Q-Exactive Orbitrap instrument (ThermoScientific, NJ, USA).
Chromatography and Mass Spectrometry
(LC-MS/MS) Methods
Protein samples were analyzed using LC-MS/MS (Q-Exactive).
Data dependent acquisition (DDA) settings for these MS
experiments followed our previous work (Ojo et al., 2020;
Pearson et al., 2020). DDA settings were as follows: full-scan
MS resolution = 140 000 full width at half maximum at 200
m/z, full-scan range = 380–1250 m/z, isolation width = 1.2
m/z, higher energy C-trap dissociation relative collision energy
= 29, a minimum m/z setting of 100 m/z was used for all MS2
spectra, MS2 resolution = 17 500, dynamic exclusion = 180 s,
and a Top 15 high/low duty cycle was used for precursor ion
selection. We used a narrow isolation window and an ultra-
long gradient setting to minimize the deleterious effects on
quantitative accuracy that typically result from co-isolation of
isobaric precursors without resorting to MS3-based method.
Data Processing and Statistical Analysis of
Proteomics Data
We surveyed our amalgamated data-files and added other
modifications to our search criteria if deemed necessary, using
the PMi preview software. Preview results were used to choose
the precursor and fragment ion mass tolerances (4-ppm, 0.02-
Da, respectively) and dynamic modifications. We used the
following settings to search the data using SEQUEST and
BYONIC as the search algorithms, and Uniprot human database
(FEB/2018). Dynamic modifications –Oxidation/+15.995 Da
(M), Methyl/+14.016 Da (E), Deamidated/+0.984 Da (N, Q),
static modifications of TMT10plex/+229.163 Da (N-Terminus,
K), Carbamidomethyl +57.021 (C). Only unique peptides were
considered for our final quantification. We used the Percolator
feature of Proteome Discoverer for SEQUEST, and used the
target-decoy feature, to set a false discovery rate (FDR) of 0.01 for
Byonic. The peptides passing this stringent cutoff FDR rate were
subsequently exported for data cleaning and statistical analysis.
Master proteins only underwent quantitative analysis if they were
identified in at least 50% of the total number of plexes. Log2
fold change and expression p-value between the two groups
of interest after log transformation and parametric analyses
were subsequently uploaded into ingenuity pathway analyses
(IPA) where molecules and pathways, diseases and biofunctions,
associated networks and upstream regulators unique to each
group comparison(s) were identified. Only master proteins with
a significant non-adjusted p-value (cut-off <0.05) were uploaded
into IPA. We have deposited the mass spectrometry proteomic
data into the ProteomeXchange Consortium via the PRIDE
partner repository (Vizcaíno et al., 2016). Our datasets can be
located with the unique identifier—PXD023340.
Ingenuity Pathway Analysis
All datasets of significantly modulated proteins from our group
comparisons were uploaded into the Ingenuity Pathway Analysis
software [IPA, Ingenuity R© Systems (Krämer et al., 2014)] to
map them onto known networks of protein interactions in
the knowledgebase. We further used the IPA knowledgebase
to further determine the significantly regulated Canonical
pathways/disease and biofunctions and biological significance of
CAA/AD and age dependent changes in the cerebrovasculature.
Our core analysis settings involved the following—Ingenuity
Knowledge base as reference set, maximum number of 35
molecules per network, and a maximum number of 25
networks for analysis. Only experimentally observed knowledge
was considered in our analyses. We controlled for data
sources, species, and tissue type/cell lines at the time of
analysis in IPA. Core analysis identified canonical pathways
shown to be significantly altered in response to age and
CAA/AD pathogenesis as a result of significantly regulated
proteins represented in those pathways/biofunctions. Statistical
significance of the relationship between uploaded dataset and
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the identified pathways/biofunctions was measured using two
methods: 1) Ratio of the number of molecules from the data set
that map to a pathway/biofunction divided by the total number
of molecules in that pathway/ biofunction knowledgebase in
IPA. 2) Fisher’s exact test, to calculate a p-value determining
the probability that the association between the proteins in the
dataset and the pathway/biofunctions are explained by chance
alone. P-values were considered to be significant in these studies
when P < 0.01. Upstream regulator analysis was used to predict
the upstream transcriptional master regulators in our proteomic
dataset, and this was generated using the Ingenuity R© Knowledge
Base. An overlap P∗value was generated based on analyses of
the significant overlap between proteins/genes in our dataset
and known targets modulated by the transcriptional regulator
or Upstream master regulator. The activation z-score algorithm
was used to make predictions. For the network analysis, a
p-score [–log10 (p-value)] according to the fit of the set of
supplied proteins and a list of biological functions stored in the
Ingenuity Knowledge Base were generated. An experimentally
set confidence with only the inclusion of human data and a
size constraint of 35 focus molecules per network was applied
as described above. We considered both direct and indirect
relationships for the network analysis.
RESULTS
Demographics and Clinical Background of
Patient Population
In this study, we used 44 total brain cerebrovascular specimens
from the inferior frontal gyrus obtained from young healthy
controls (9 cases), aged non-demented controls (15 cases) and
Alzheimer’s disease (AD) patients (20 cases; 10 cases each with
Low or High CAA score) — (Table 1).
Most of the AD cases and matched aged non-demented
control cases comprised of septuagenarians and octogenarians
(Table 1). On average, aged non-demented control cases (87.4
± 1.5 yrs) were older than both AD cases with low (85.5 ± 2.9
yrs) and high (81 ± 4.4 yrs) CAA scores. While, the young
control group had an average age of 45.83± 4.39 yrs. Each group
consisted of mixed genders, and on average, there were more
female in the AD cases (30-40% males) than the control cases
(56-60% males)—(Table 1).
AD cases with low or high CAA scores consisted of 40%
or 67% APOE4 allele carriers, respectively; while only 20% of
aged non-demented control cases were APOE4 allele carriers.
The young healthy control cohort consisted of 60% APOE4 allele
carriers (Table 1).
FIGURE 1 | Cerebral amyloid angiopathy [CAA] (A), mean brain weight in grams (B) and neuropathological scores for Neuritic Plaque (C), Total Amyloid plaque score
(D), NFT staging (E), and total tangle pathology score (F). Data was analyzed by one way ANOVA with Holm-Sidak post-hoc test. *P < 0.05 and ****P < 0.0001 (for
Control Aged vs. High CAA group); +P < 0.05 and ++++P < 0.0001 (for Control Aged vs. Low CAA group); $P < 0.05, and $$$$P < 0.0001 (for Low vs. High CAA
group).
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No statistical difference was observed in CAA score for AD
cases with low CAA staging compared to their age matched
counterparts (Figure 1A). However, there was a significant
reduction in brain weight (Figure 1B), and a significant increase
in Amyloid Plaque and Tangle pathology in low CAA [AD] cases
compared to matched controls (Figures 1C–F).
There was a significant reduction in the brain weight of
high CAA compared to aged matched controls (Figure 1B).
There was also a significant increase in Amyloid plaque and
Tangle pathology (Figures 1C–F), accompanied by the lowest
performances in the last MMSE scores (see Table 1).
Only Tangle pathology was found to be statistically
significant between low vs. high CAA Alzheimer’s disease cases
(Figure 1F).
Proteomic Profiles, Cell Type Specific
Changes, Altered Canonical Pathways and
Upstream Regulators Between Young vs.
Aged Control Cerebrovascular Tissue
A Ten multiplex TMT isobaric tag approach was used to
study the proteomic profiles of brain cerebrovascular tissue
from the inferior frontal gyrus of AD and non-demented
young and aged-matched control cases. We identified a total
of 13,760 total peptide spectrum matches and 1,271 non-
redundant master protein groups (Figure 2A). To determine
the cell type constituents of our enriched cerebrovascular
tissue we identified cell specific protein markers in our
proteomic dataset using the single cell sequencing resource
from the PanglaoDB omic database. We measured the
relative protein expression levels of these specific markers
associated with these different cell types in control cases,
and observed that there was a relatively high expression
of markers associated with pericytes (AOC3, COL1A1,
MYO1B) and endothelia (CLEC14A, VWF, Cav1, PLEC) in
our enriched cerebrovascular fractions (Figures 2B,C). In
rank order, this was followed by smooth muscle cells (EHD2,
ITGA1, MTL9), astrocyte (GFAP, AQP4, S100β, APOE) and
oligodendrocytes (CNP, PLP1, MBP)–Figure 2C. Neurons and
microglia specific markers were also observed but showed
very low expression levels relative to the other cell types above
(Figure 2C).
Statistical analyses of the proteomic datasets first involved
comparing significant changes in master proteins between
young vs. aged control cases. We noted 154 significant
proteins out of 1,271 that were significantly altered
between young vs. aged control cases (see Venn diagram
in Figures 2D,F). Volcano plot in Figure 3A depicts the
correlation between Log2 fold change and negative Log10
p-value of the (total and significantly regulated) master
proteins identified in our proteomic analyses; 81 proteins
were significantly upregulated while 73 proteins were
significantly downregulated (Figure 3A; see pie chart inset).
The List of the Top 20 proteins significantly altered between
young vs. aged control cases is shown in Table 2. For a
complete list of all proteins, see Supplementary Table 1,
corresponding protein network interaction can also be found in
Supplementary Figure 1.
The majority of these proteomic changes were attributed to
cytoskeletal, cytosolic, nuclear and extracellular cell membrane
proteins, including proteins associated with mitochondrial
bioenergetics (Figure 4A).
From the list of 154 proteins significantly regulated, we
identified the number of proteins that were known to specifically
originate from a particular cerebrovascular cell type, and
expressed this as a percentage, to capture the specific contribution
of each cerebrovascular cell type in our proteomic findings. We
observed that most of the significant changes (P < 0.05) in
our proteomic datasets between young vs. aged control cases
were associated with endothelial cell specific markers (67%) and
smooth muscle cell markers (33%) (Figures 3B, 4B).
Ingenuity pathway analyses (IPA) identified 32 pathways
significantly impacted between young vs. aged control cases
(Figure 3C). The top 3 pathways include downregulation
of synaptogenesis signaling pathways, Reelin signaling and
Chemokine signaling. Heat map in Figure 3D, shows the number
of proteins associated with these Top three pathways, and their
directionality of change.
We interrogated the Top 5 Upstream Regulators mediating
the changes observed in significantly regulated proteins identified
from our analyses (Figure 3E). IPA analyses identified a
significant overlap in our dataset and known targets regulated
by these five Upstream regulators, namely (in rank order of
significance)–MAPT (microtubule associated protein tau), APP
(amyloid precursor protein), RTN4 (Reticulon 4 or Nogo),
PSEN1 (Presenilin 1), and MYC (Proto-Oncogene, BHLH
Transcription Factor).
Proteomic Profiles, Cell Type Specific
Changes, Altered Canonical Pathways, and
Upstream Regulators Between AD (Low
CAA Score) vs. Aged-Matched Control
Cerebrovascular Tissue
Despite the profound clinicopathological differences observed
between AD cases with low CAA compared to their age-
matched counterparts, at the vascular level, we only observed
37 significant proteins out of 1,271 that were significantly
altered (see Venn diagram in Figures 2E,F). Volcano plot in
Figure 5A depicts the correlation between Log2 fold change and
negative Log10 p-value of the (total and significantly regulated)
master proteins identified in our proteomic analyses; seven
proteins were significantly upregulated while 30 proteins were
significantly downregulated (Figure 5A; see pie chart inset).
The List of the Top 20 proteins significantly altered between
Low CAA [AD] vs. age-matched control is shown in Table 3.
For a complete list of all proteins, see Supplementary Table 2,
corresponding protein network interaction can also be found in
Supplementary Figure 2.
The majority of these proteomic changes were also attributed
to cytoskeletal, cytosolic and extracellular cell membrane
proteins, including proteins associated with mitochondrial
bioenergetics (Figure 4A).
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From the list of 37 proteins significantly regulated between
AD (low CAA score) vs. aged-matched controls, we observed
that most of the significant changes (P < 0.05) were
associated primarily with smooth muscle cell specific markers
(Figures 4B, 5B).
Ingenuity pathway analyses (IPA) identified 6 pathways
significantly impacted between AD (low CAA score) vs. aged-
matched controls (Figure 5C). The top 3 pathways include
alteration in sirtuin signaling, oxidative phosphorylation and
leukocyte extravasation signaling. Heat map in Figure 5D, shows
the number of proteins associated with these Top three pathways,
and their corresponding fold-change.
IPA analyses identified CLPP (Caseinolytic Mitochondrial
Matrix Peptidase Proteolytic Subunit), RICTOR (rapamycin-
insensitive companion of mammalian target of rapamycin),
TLE3 (Transducin-like enhancer protein 3), and MMP12
(matrix metalloproteinase protein 12) as the top four Upstream
Regulators driving the proteomic changes between AD (low CAA
score) vs. aged-matched controls (Figure 5E).
Proteomic Profiles, Cell Type Specific
Changes, Altered Canonical Pathways, and
Upstream Regulators Between AD (High
CAA Score) vs. Aged-Matched Control
Cerebrovascular Tissue
We noted 230 significant proteins out of 1,271 were significantly
altered between AD (high CAA score) vs. aged-matched
control (see Venn diagram in Figures 2E,F). Volcano plot in
Figure 6A depicts the correlation between Log2 fold change
and negative Log10 p-value of the (total and significantly
regulated) master proteins identified in our proteomic analyses;
FIGURE 2 | Summary of liquid chromatography/mass spectrometry (LC/MS) and proteomic analyses of isolated cerebrovascular tissue from the inferior frontal gyrus
in Alzheimer’s disease (AD) and young/aged matched control cases. (A) Shows identified total number of quantified spectra, peptide spectrum matches and
non-redundant master protein groups from all plexes used for quantitative proteomic analyses of (B) isolated cerebrovascular tissue from the inferior frontal gyrus
[IFG]. (C) Data shows expression levels of distinct genes associated with specific cell types identified from our proteomic analyses of the isolated cerebrovasculature.
Data represent abundant ratio expressed in arbitrary units. Venn diagram in (D,E) shows overlapping significantly regulated proteins by t-test in the comparisons
between young vs. aged healthy controls cases and Low CAA vs. High CAA vs. Age-matched controls, respectively. (F) Shows heat map of proteins identified from
our proteomic analyses between young vs. aged controls, aged control vs. low CAA, aged controls vs. high CAA and low vs. high CAA groups (data represent Log2
fold change).
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21 proteins were significantly upregulated while 209 proteins
were significantly downregulated (Figure 6A; see pie chart inset).
The List of the Top 20 proteins significantly altered between
high CAA [AD] vs. age-matched control is shown in Table 4.
For a complete list of all proteins, see Supplementary Table 3,
corresponding protein network interaction can also be found in
Supplementary Figure 3.
The majority of these proteomic changes were also attributed
to cytoskeletal, cytosolic and extracellular cell membrane
proteins, including also modest involvement of proteins
associated with cell adhesion molecules and mitochondrial
bioenergetics, and nuclear proteins (Figure 4A).
From the list of 230 proteins significantly regulated between
AD (high CAA score) vs. aged-matched controls, we observed
that most of the significant changes (P < 0.05) were associated
with pericytes and smooth muscle cells (both 25%), perivascular
astrocytes andmicroglia/macrophage (both 17%) and endothelial
cell specific markers (16%) (Figures 4B, 6B).
Ingenuity pathway analyses (IPA) identified 35 pathways
significantly impacted between AD (high CAA score) vs. aged-
matched controls (Figure 6C). The top 3 pathways include
alterations in oxidative phosphorylation, Sirtuin signaling and
TCA cycle II. Heat map in Figure 6D, shows the number
of proteins associated with these top 3 pathways, and their
corresponding fold-change.
IPA analyses identified MAPT (microtubule associated
protein tau), RICTOR (rapamycin-insensitive companion
of mammalian target of rapamycin), TLE3 (Transducin-like
enhancer protein 3), PSEN1 (Presenilin 1) and APP (amyloid
precursor protein) as the top five Upstream Regulators driving
the proteomic changes between AD (high CAA score) vs.
aged-matched controls (Figure 6E).
Proteomic Profiles, Cell Type Specific
Changes, Altered Canonical Pathways, and
Upstream Regulators Between Low vs.
High CAA Alzheimer’s Disease
Cerebrovascular Tissue
Eighty four significant proteins out of 1,271 were significantly
altered between low vs. high CAA Alzheimer’s disease
cerebrovascular tissue (see Venn diagram in Figures 2E,F).
Volcano plot in Figure 7A depicts the correlation between
Log2 fold change and negative Log10 p-value of the (total
and significantly regulated) master proteins identified
in our proteomic analyses; 16 proteins were significantly
upregulated while 68 proteins were significantly downregulated
(Figure 7A; see pie chart inset). The List of the Top 20 proteins
significantly altered between low vs. high CAA Alzheimer’s
disease cerebrovascular tissue is shown in Table 5. For a
FIGURE 3 | Proteomic changes, cell origin, signaling pathways, upstream regulator factors observed in the cerebrovasculature isolated from the inferior frontal gyrus
of young and aged controls. (A) Volcano plot of differentially expressed proteins in young and aged controls (pie chart inset shows up/down-regulated proteins,
significant cut off set at 1.3 and red and blue points indicated up- or down-regulated significant proteins, respectively). (B) Pie Chart show origin of cell types where
significant proteins from the comparisons between young and aged controls are observed. Data are generated from the number of significantly regulated proteins per
specific cell type (from the PanglaoDB omic database), expressed as a percentage. (C) Canonical pathways identified from ingenuity pathway analyses [data depict
–log10 (P-value) and Z score generated from Fischer test of an overlap with the IPA knowledgebase; blue—downregulated and red—upregulated], and (D) shows
heat map of the top 3 pathways and the corresponding number of significantly regulated proteins altered per pathway and their Log2 fold change expression level. (E)
Shows Top 5 identified upstream regulators from the ingenuity pathway analyses of differentially regulated proteins in young vs. aged control cases.
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TABLE 2 | List of Top 25 proteins significantly regulated in the inferior frontal gyrus cerebrovasculature of young and aged control cases.
Gene name Uniprot ID Protein name Biological function Log2FC –Log10
(P-value)
CSPG-2 Q59FG9 Chondroitin sulfate proteoglycan 2
(Versican)
Cell adhesion 0.47 3.88
HSPA12A A0A1B0GTF3 Heat shock 70 kDa protein 12A Heatshock proteins (found in
atherosclerotic lesions)
0.33 3.74
NEFH P12036 Neurofilament heavy polypeptide Axon development 0.46 3.44
NEFL P07196 Neurofilament light polypeptide Anterograde axonal transport 0.63 3.32
CAMK1D Q8IU85 Calcium/calmodulin-dependent protein
kinase type 1D
Inflammatory response 0.31 3.2
INA Q16352 Alpha-internexin (Alpha-Inx) (66 kDa
neurofilament protein)
Cell differentiation 0.47 3.2
PADI2 Q9Y2J8 Protein-arginine deiminase type-2 Cellular response to leukemia inhibitory
factor
0.26 3.03
OGDHL Q9ULD0 2-oxoglutarate dehydrogenase-like,
mitochondrial
Glycolytic process 0.38 2.94
HPCAL1 P37235 Hippocalcin-like protein 1 Calcium binding protein 0.21 2.52
MAPRE3 B2R5W6 Microtubule-associated protein, RP/EB
family, member 3
Cell cycle 0.38 2.5
FTH1 Q6NS36 Ferritin (Fragment) Cellular iron ion homeostasis 0.27 2.5
HEL-S-303 V9HW12 Epididymis secretory protein Li 303 Activation of MAPK activity −0.25 2.44
EPB41L3 Q9Y2J2 Band 4.1-like protein 3 Actomyosin structure organization 0.24 2.4
MAP1B A0A024RAM4 Microtubule-associated protein 1B Microtubule cytoskeleton organization 0.39 2.4
ADD2 P35612 Beta-adducin (Erythrocyte adducin subunit
beta)
Actin cytoskeleton organization 0.4 2.37
FREP1 Q4L233 Brain-specific protein p25 alpha (Fibroblast
growth factor-2 repression protein-1)
Microtubule bundle formation 0.46 2.36
SEPTIN6 Q8NFH9 MLL/SEPTIN6 fusion protein Histone methyltransferase activity 0.4 2.35
DYNC1H1 Q14204 Cytoplasmic dynein 1 heavy chain 1 Antigen processing and presentation of
exogenous peptide antigen via MHC class
II
0.24 2.32
ERP29 P30040 Endoplasmic reticulum resident protein 29 Activation of MAPK activity −0.68 2.3
KHDRBS1 Q07666 KH domain-containing, RNA-binding,
signal transduction-associated protein 1
G1/S transition of mitotic cell cycle −0.55 2.28
PRPF40A O75400 Pre-mRNA-processing factor 40 homolog
A (Fas ligand-associated factor 1)
Cell cycle −0.7 2.26
PCSK1N Q9UHG2 ProSAAS (Proprotein convertase
subtilisin/kexin type 1 inhibitor)
Neuropeptide signaling pathway −1.01 2.25
CK B4DP56 Creatine kinase Phosphocreatine biosynthetic process 0.47 2.25
HNRNPA3 P51991 Heterogeneous nuclear ribonucleoprotein
A3
mRNA splicing, via spliceosome −0.5 2.25
NSAP1 B2R8Z8 Synaptotagmin binding, cytoplasmic RNA
interacting protein
mRNA stability −0.73 2.19
Data are expressed as the negative Log10 of the p-value (significance cut off set at >1.3 or P < 0.05), and the Log 2 fold change between young vs. aged control cases.
complete list of all proteins, see Supplementary Table 4,
corresponding protein network interaction can also be found in
Supplementary Figure 4.
The majority of these proteomic changes were also attributed
to cytoskeletal, cytosolic and extracellular cell membrane
proteins, including also involvement of proteins associated with
cell adhesion molecules and mitochondrial bioenergetics, and
nuclear proteins (Figure 4A).
From the list of 84 proteins significantly regulated between
low vs. high CAA Alzheimer’s disease cerebrovascular tissue, we
observed that most differentially significant changes (P < 0.05)
were associated with smooth muscle cells (56%), followed by
pericytes (22%), and astrocytes/endothelial cell specific markers
(each 11%) (Figures 4B, 7B).
Ingenuity pathway analyses (IPA) identified 9 pathways
significantly between low vs. high CAA Alzheimer’s disease
cerebrovascular tissue (Figure 7C). The top 3 pathways
include alterations in TCA cycle II oxidative phosphorylation
and mitochondrial dysfunction/gluconeogenesis. Heat
map in Figure 7D, shows the number of proteins
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FIGURE 4 | Ratio of significantly regulated proteins per subcellular localization or biological function and Cell specific proteins expression levels identified in
cerebrovasculature of young and aged controls, and AD cases staged by low vs. high CAA score. (A) Data shows percentage of significantly altered proteins
associated with a biological function or subcellular localization. ECM—Extracellular matrix protein, CAM—cellular adhesion molecule. (B) Data shows cell specific
proteins expression levels. Proteins in red represents smooth muscle cell markers, purple (astrocytes), yellow (microglia), pericytes (green), blue (endothelial cells). Data
shows Log2 fold change (note: not all cell specific proteins depicted passed the set cut-off value of P < 0.05).
associated with these top 3 pathways, and their
corresponding fold-change.
IPA analyses identified MAPT (microtubule associated
protein tau), CLPP (CaseinolyticMitochondrialMatrix Peptidase
Proteolytic Subunit), KDM5A (Lysine-specific demethylase 5A)
and APP (amyloid precursor protein) as the top four Upstream
Regulators driving the proteomic changes between low vs. high
CAA Alzheimer’s disease cerebrovascular tissue (Figure 7E).
DISCUSSION
We employed our state-of-the-art proteomic platform to conduct
a detailed unbiased characterization of changes in protein
expression levels, and molecular pathways significantly altered
from cerebrovascular tissue isolated from the inferior frontal
gyrus of young and aged controls and AD brains staged
by CAA severity. Endothelial and mural cells, supported by
other perivascular cell types (e.g., perivascular astrocytes),
predominantly comprise the cerebrovascular fraction isolated
from these autopsy specimens. Our analyses revealed unique
proteomic changes and molecular pathways driven by age and
CAA severity in the sequelae of AD pathogenesis.
Specifically, we observed 150 significantly regulated proteins
in young vs. aged control cerebrovessels. With respect to the
cell specific markers identified from this group comparison,
we noted that significant changes were mainly associated with
smooth muscle and endothelial cells. Chemokine and reelin
signaling, synaptogenesis signaling, hypoxia inducible factor 2α
(HIF2α) and Eukaryotic initiation factor 2 (EIF2) signaling
pathways were the top 5 pathways significantly upregulated
with age, thus indicating that inflammation, alteration in cell
to cell communication, protein-synthesis and oxidative stress
may be prominent features of cerebrovessel aging. It is worthy
of note that synaptogenesis was identified as one of the top
signaling pathways altered. The reason behind this change
remains unknown. Neuronal end-feet processes are known to
connect with endothelial cells to regulate neurovascular coupling,
however, our initial analyses showed very low expression levels
of neuronal specific markers in the cerebrovascular fractions
compared to endothelial and mural cell specific markers. An
alternative explanation is that other enriched cell types such as
astrocytes (Farhy-Tselnicker and Allen, 2018) or endothelial cells
(Wu et al., 2019) could be the mediators of these synaptogenesis
signaling pathways.
We also report unique proteomic changes in cerebrovessels
of AD patients compared to age-matched control counterparts.
Firstly, we stratified AD cases into two distinct groups based on
low (<4) and high CAA (>8) scores. Generally, AD patients
with high CAA staging had the worst MMSE results, the smallest
brain weight, and most severe amyloid plaque and tau pathology
compared to AD cases with low CAA staging and age-matched
controls. From our analyses, we observed a significantly greater
proteomic response in cerebrovessels between AD cases with
high CAA staging vs. age-matched controls (230 significantly
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FIGURE 5 | Proteomic changes, cell origin, signaling pathways, upstream regulator factors observed from the cerebrovasculature isolated from the inferior frontal
gyrus of low CAA vs. aged-matched control cases. (A) Volcano plot of differentially expressed proteins in low CAA vs. aged-matched control cases (pie chart inset
shows up/down-regulated proteins, significant cut off set at 1.3 and red and blue points indicated up- or down-regulated significant proteins, respectively). (B) Pie
Chart show origin of cell types where significant proteins from the comparisons between low CAA vs. aged-matched control cases are observed. Data are generated
from the number of significantly regulated proteins per specific cell type (from the PanglaoDB omic database), expressed as a percentage. (C) Canonical pathways
identified from ingenuity pathway analyses [data depict –log10 [P-value] and Z score generated from Fischer test of an overlap with the IPA knowledgebase;
blue—downregulated and red—upregulated], and (D) shows heat map of the top 3 pathways and the corresponding number of significantly regulated proteins altered
per pathway and their Log2 fold change expression level. (E) Shows Top 4 identified upstream regulators from the ingenuity pathway analyses of differentially
regulated proteins in low CAA vs. aged-matched control cases (light blue highlighted text indicates that the upstream regulator is predicted to be activated).
regulated protein), compared to AD cases with low CAA staging
vs. age-matched counterparts (37 significantly regulated protein).
The latter appeared to indicate an upregulation in Sirtuin
signaling and downregulation in oxidative phosphorylation,
leukocyte extravasation, vascular endothelial growth factor
(VEGF) signaling and integrin linked kinase (ILK) signaling.
While the former also indicated an upregulation in Sirtuin
signaling and downregulation in oxidative phosphorylation, but
also a host of different pathways such as down regulation of
the TCA cycle II, mammalian target of rapamycin (mTOR),
hypoxia inducible factor 1α (HIF1α), Ciliary neurotrophic
factor (CNTF), and N-Formylmethionyl-leucyl-phenylalanine
(fMLP), interleukin 3 (IL3), chemokine receptor type 3 (CCR3),
CXC chemokine receptor type 4 (CXCR4), thrombin and
necroptosis signaling pathways. Thus suggesting an alteration
in energy bioenergetic, oxidative damage, chemotactic and
inflammatory signaling, BBB damage and cell death with
increasing CAA severity.
With respect to the cell-type specific proteomic changes, we
only noted significant changes in smooth muscle cell specific
markers in AD cases with a low CAA score compared to their
age- matched controls, possibly indicating an early involvement
of arteriolar smoothmuscle cells in CAA pathogenesis as amyloid
deposits form around arteriole vessels. Significant changes in
pericyte, smooth muscle cell, microglia, astrocyte and endothelial
cell specific markers were observed in AD cases with a high CAA
score compared to their age-matched controls, thus signifying the
involvement of multiple cerebrovascular/perivascular cell types
in the late degenerative stages of CAA.
To further delineate the differences between AD cases with
low vs. high CAA scores, we also compared proteomic
changes between their cerebrovessels and observed 84
significantly regulated proteins. Some of the main pathways
identified involved downregulation of TCA cycle II,
oxidative phosphorylation, mitochondrial dysfunction, and
gluconeogenesis, further supporting the role of deficits in energy
bioenergetics within cerebrovessels with CAA severity. With
respect to changes in cell-type specific markers, we again revealed
that smooth muscle cell specific markers played the greatest
influence across the neuropathological staging of CAA in AD
cases, followed by pericytes, and endothelial cells/astrocytes.
The role of the cerebrovasculature in driving AD pathogenesis
has long been discussed. The vascular hypothesis was described
a few decades ago to provide a vascular preclinical etiology
for AD. Early evidence showed that cerebral perfusion,
cortical blood flow and metabolic deficits were observed
in MCI patients and those who go on to develop AD (De
la Torre and Mussivand, 1993; Binnewijzend et al., 2016;
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TABLE 3 | List of Top 25 proteins significantly regulated in the inferior frontal gyrus cerebrovasculature of low CAA vs. aged-matched control cases.
Gene name Uniprot ID Protein name Biological function Log2FC –Log10 (P
value)
ACTN2 P35609 Alpha-actinin-2 (Alpha-actinin skeletal
muscle isoform 2)
Actin filament uncapping 0.32 2.33
TPM4 P67936 Tropomyosin alpha-4 chain (TM30p1)
(Tropomyosin-4)
Actin filament organization −0.31 2.04
HPCAL1 P37235 Hippocalcin-like protein 1
(Calcium-binding protein BDR-1)
Calcium binding protein −0.18 1.96
TUFM P49411 Elongation factor Tu, mitochondrial Mitochondrial translational elongation −0.2 1.91
RPSA A0A0C4DG17 (37 kDa laminin receptor precursor)
(37LRP)
Ribosomal small subunit assembly −0.23 1.91
ACTN1 P12814 Alpha-actinin-1 cytoskeletal isoform Actin crosslink formation −0.2 1.88
DECR1 A0A024R9D7 2,4-dienoyl CoA reductase 1,
mitochondrial, isoform
Positive regulation of cold-induced
thermogenesis
−0.27 1.83
MCH-2V Q53G34 Mitochondrial carrier homolog 2 variant Mitochondrial metabolic pathways −0.42 1.73
PRELP P51888 Proline-arginine-rich end leucine-rich
repeat protein
Cell aging −0.33 1.69
PIPSL A2A3N6 Putative PIP5K1A and PSMD4-like protein Phosphatidylinositol phosphate kinase
activity
−0.41 1.69
DYNC1I1 O14576 Cytoplasmic dynein 1 intermediate chain 1 Antigen processing and presentation of
exogenous peptide antigen via MHC class
II
−0.29 1.68
HDGFL3 Q9Y3E1 Hepatoma-derived growth factor-related
protein 3
Microtubule polymerization −0.27 1.59
FBN1 P35555 Fibrillin-1 Activation of protein kinase A activity 0.35 1.58
PHB A8K401 Prohibitin Activation of phospholipase C activity −0.19 1.57
NDUFB4 O95168 NADH dehydrogenase [ubiquinone] 1 beta
subcomplex subunit 4
Mitochondrial electron transport, NADH to
ubiquinone
−0.33 1.57
APP A0A218KGR2 Alpha-secretase C-terminal fragment
(Amyloid-beta A4 protein)
Endocytosis 0.85 1.54
A8K4W2 ATP synthase F(0) complex subunit B1,
mitochondrial
ATP synthesis coupled proton transport −0.4 1.53
MYL6 B7Z6Z4 Myosin light polypeptide 6 ATPase cellular motor protein. −0.19 1.52
IMMT Q16891 MICOS complex subunit MIC60 (Cell
proliferation-inducing gene)
Cristae formation −0.19 1.51
TOMM70 O94826 Mitochondrial import receptor subunit
TOM70
Macroautophagy −0.3 1.48
HEL-S-99n V9HW25 Calreticulin Binds misfolded proteins preventing
export from the ER
−0.5 1.47
ABR A0A1C7CYZ0 Active breakpoint cluster region-related
protein
Intracellular signal transduction −0.17 1.45
ACTN4 O43707 Alpha-actinin-4 Actin filament bundle assembly −0.17 1.44
FARP1 C9JME2 FERM, ARHGEF and pleckstrin
domain-containing protein 1
Dendrite morphogenesis −0.24 1.44
TPR P12270 Nucleoprotein (Translocated promoter
region protein)
mRNA transport −0.64 1.41
Data are expressed as the negative Log10 of the p-value (significance cut off set at >1.3 or P < 0.05), and the Log 2 fold change between low CAA vs. aged-matched control cases.
Hays et al., 2016; de la Torre, 2018), beginning many
years prior to the onset of their neurological symptoms.
Seminal findings from the Nun dementia study (Snowdon,
1997) involving catholic sisters between 75 to 107yrs also
demonstrated a prominent role for vascular lesions such as
lacunar infarcts at autopsy, with these lesions serving as a
protagonist for reducing the neuropathological threshold
required for defining the staging of AD dementia (Nagy
et al., 1997). Other vascular related morphological lesions
have also been observed at autopsy in demented and non-
demented elderly patients such as degeneration of small
blood vessels, capillaries and perivascular end-feet processes
(Miyakawa and Kuramoto, 1989; Hashimura et al., 1991;
Kimura et al., 1991; Vinters et al., 1994; Kalaria, 1996; Farkas
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FIGURE 6 | Proteomic changes, cell origin, signaling pathways, upstream regulator factors observed from the cerebrovasculature isolated from the inferior frontal
gyrus of high CAA vs. aged-matched control cases. (A) Volcano plot of differentially expressed proteins in high CAA vs. aged-matched control cases (pie chart inset
shows up/down-regulated proteins, significant cut off set at 1.3 and red and blue points indicated up- or down-regulated significant proteins, respectively). (B) Pie
Chart show origin of cell types where significant proteins from the comparisons between high CAA vs. aged-matched control cases are observed. Data are generated
from the number of significantly regulated proteins per specific cell type (from the PanglaoDB omic database), expressed as a percentage. (C) Canonical pathways
identified from ingenuity pathway analyses [data depict –log10 (P-value) and Z score generated from Fischer test of an overlap with the IPA knowledgebase;
blue—downregulated and red—upregulated], and (D) shows heat map of the top 3 pathways and the corresponding number of significantly regulated proteins altered
per pathway and their Log2 fold change expression level. (E) Shows Top 5 identified upstream regulators from the ingenuity pathway analyses of differentially
regulated proteins in high CAA vs. aged-matched control cases (light blue highlighted text indicates that the upstream regulator is predicted to be activated).
et al., 2000; Farkas and Luiten, 2001; Hauw et al., 2002;
Zekry et al., 2002; Fernando and Ince, 2004; Østergaard
et al., 2013); mitochondrial abnormalities and deposition of
phagolysosomes and lipofuscin in cerebrovascular cells (Terry
et al., 1964; Miyakawa and Kuramoto, 1989), blood brain
barrier damage (Deane and Zlokovic, 2007) and immune
cell extravasation (Itagaki et al., 1988; Rogers et al., 1988;
Togo et al., 2002; Di Marco et al., 2015; Merlini et al., 2018).
Moreover, vascular factors such as cardiovascular diseases,
atherosclerosis, diabetes mellitus, hyperhomocysteinhemia,
obesity and hypertension also increase the risk for AD in
later life (Breteler, 2000; Kivipelto et al., 2001; Duron and
Hanon, 2008; Ouldred and Bryant, 2010; de Bruijn and Ikram,
2014; O’Brien and Markus, 2014), alogether suggesting that
vascular dysfunction may play a role in contributing to AD
pathogenesis as we age. However, whether these vascular issues
are a direct prelude to AD pathogenesis or a consequence
remains elusive.
Vascular dysfunction manifested as brain hypoperfusion,
hypoxia and hypometabolism are known among the modulators
of cerebral amyloidogenesis and amyloid clearance (Mosconi,
2005; Zhang et al., 2007; Mawuenyega et al., 2010; Govindpani
et al., 2019). In turn, deposition of amyloid-beta toxic species on
vascular walls can also lead to changes typified by impairment
in vascular hemodynamics and vessel rigidity leading to arterial
and arteriole narrowing, increased cerebral blood pressure
and further weakening of the vascular walls contributing to
hypoperfusion and hypometabolism (Kalback et al., 2004; Tian
et al., 2004). We partly observed this in our study in the form
of changes to basement membrane proteins (implicating age-
related arteriolosclerosis), activation of hypoxia inducible factor
HIF1α, deficits in cerebrovessel energy bioenergetics and also
from the strong correlation between CAA severity and the extent
of proteomic changes in cerebrovessels. Our previous work
has also confirmed a reduction in mural cell markers such as
PDGFRβ and αSMA by ELISA method in the same batch of
control and AD cerebrovessels used in this study (Ojo et al.,
2021), signaling a possible degeneration of these cells in AD.
These direct toxic effects of amyloid species have been confirmed
in isolated cerebral tissue, in transgenic mouse models with
CAA and cerebrovascular cell culture models after exposure
to toxic amyloid species (Paris et al., 2003; Park et al., 2004;
Tong et al., 2005; Nortley et al., 2019). As our proteomic study
design focused on the end-stage analyses of cerebrovessels, we
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TABLE 4 | List of Top 25 proteins significantly regulated in the inferior frontal gyrus cerebrovasculature of high CAA vs. aged-matched control cases.
Gene name Uniprot ID Protein name Biological function Log2FC –Log10 (P
value)
NDUFA9 Q16795 NADH dehydrogenase [ubiquinone] 1
alpha subcomplex subunit 9,
mitochondrial
Circadian rhythm −0.38 4.55
DECR1 A0A024R9D7 2,4-dienoyl CoA reductase 1,
mitochondrial, isoform
Beta-oxidation enzyme −0.7 4.13
NDUFB3 O43676 NADH dehydrogenase [ubiquinone] 1 beta
subcomplex subunit 3
Mitochondrial electron transport, NADH to
ubiquinone
−0.41 3.9
NDUFS2 O75306 NADH dehydrogenase [ubiquinone]
iron-sulfur protein 2, mitochondrial
Mitochondrial ATP synthesis coupled
electron transport
−0.39 3.75
ATP5F1E P56381 ATP synthase subunit epsilon,
mitochondrial
ATP biosynthetic process −0.63 3.72
IMMT Q16891 MICOS complex subunit MIC60 (Cell
proliferation-inducing gene 4/52 protein)
Roles in the maintenance of crista
junctions
−0.3 3.64
NDUFA5 A0A024R745 (NADH dehydrogenase [ubiquinone] 1
alpha subcomplex subunit 5)
Respiratory electron transport chain −0.68 3.63
Q59EI9 ADP,ATP carrier protein, liver isoform T2
variant
ATP transmembrane transporter activity −0.36 3.51
NEFM A5YM63 160 kDa neurofilament protein
(Neurofilament 3)
Neurofilament bundle assembly 0.51 3.34
DYNLL2 Q96FJ2 Dynein light chain 2, cytoplasmic Antigen processing and presentation of
exogenous peptide antigen via MHC class
II
−0.42 3.3
CPNE5 Q9HCH3 Copine-5 (Copine V) Cellular response to calcium ion −0.91 3.22
ACTN1 P12814 Alpha-actinin-1 cytoskeletal isoform Anchors actin to a variety of intracellular
structures
−0.37 3.2
UQCRC1 P31930 Cytochrome b-c1 complex subunit 1,
mitochondrial
Aerobic respiration −0.32 3.2
STX1A Q75ME0 STX1A protein Syntaxin 1A (Brain) Calcium-ion regulated exocytosis −0.5 3.08
AP2A1 O95782 AP-2 complex subunit alpha−1 (100 kDa
coated vesicle protein A)
Antigen processing and presentation of
exogenous peptide antigen via MHC class
II
−0.19 3.06
ATP5F1C P36542 ATP synthase subunit gamma,
mitochondrial
ATP biosynthetic process −0.42 3.01
PTPNS1 D3DVW9 Protein tyrosine phosphatase,
non-receptor type substrate 1
Negative regulator of the insulin signaling
pathway
−0.6 2.98
COX6C P09669 Cytochrome c oxidase subunit 6C Generation of precursor metabolites and
energy
−0.55 2.92
COX5B P10606 Cytochrome c oxidase subunit 5B,
mitochondrial
Mitochondrial ATP synthesis coupled
proton transport
−0.28 2.88
PHB A8K401 Prohibitin Chaperone for respiration chain proteins
and trancriptional regulation
−0.23 2.87
SLC4A4 A5JJ20 Anion exchange protein Transport of anions across cellular barriers −0.5 2.86
PRP1 B4DJ38 Pentatricopeptide repeat protein 1 Negative regulation of leucine tRNA,
mitochondria-encoded proteins and COX
activity
−0.51 2.86
NDUFA8 P51970 NADH dehydrogenase [ubiquinone] 1
alpha subcomplex subunit 8
Mitochondrial electron transport, NADH to
ubiquinone
−0.63 2.86
PKM2 A0A024R5Z9 Pyruvate kinase Glucose metabolic process −0.32 2.85
ATP5MG O75964 ATP synthase subunit g, mitochondrial
(ATPase subunit g)
Catalyzes ATP synthesis during oxidative
phosphorylation
−0.5 2.85
Data are expressed as the negative Log10 of the p-value (significance cut off set at >1.3 or P < 0.05), and the Log 2 fold change between high CAA vs. aged-matched control cases.
are unable to definitively determine whether the proteomic
changes reported herein precede amyloid or tau pathologies, or
are a consequence of these pathogenic protein species activating
the molecular cascades of cerebrovascular events. Our study
comparisons of young vs. aged control cases, and also AD
cases stratified based on their CAA staging, does seem to point
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FIGURE 7 | Proteomic changes, cell origin, signaling pathways, upstream regulator factors observed from the cerebrovasculature isolated from the inferior frontal
gyrus of low and high CAA [AD] cases. (A) Volcano plot of differentially expressed proteins in low vs. high CAA [AD] cases (pie chart inset shows up/down-regulated
proteins, significant cut off set at 1.3 and red and blue points indicated up- or down-regulated significant proteins, respectively). (B) Pie Chart show origin of cell types
where significant proteins from the comparisons between low and high CAA [AD] cases are observed. Data are generated from the number of significantly regulated
proteins per specific cell type (from the PanglaoDB omic database), expressed as a percentage. (C) Canonical pathways identified from ingenuity pathway analyses
(data depict –log10 [P-value] and Z score generated from Fischer test of an overlap with the IPA knowledgebase; blue—downregulated and red—upregulated), and
(D) shows heat map of the top 3 pathways and the corresponding number of significantly regulated proteins altered per pathway and their Log2 fold change
expression level. (E) Shows Top 4 identified upstream regulators from the ingenuity pathway analyses of differentially regulated proteins in low and high CAA [AD]
cases (light blue highlighted text indicates that the upstream regulator is predicted to be activated).
toward early cerebrovascular changes involving disturbances in
energy metabolisms, oxidative stress and inflammation, which
could have significant ramifications for brain and cerebrovascular
physiology later in life.
To date, only few proteomic studies have been conducted to
investigate brain vascular abnormalities in AD. Manousopoulou
et al. (2017) used global quantitative proteomic analysis to
interrogate endophenotypic profiles in large leptomeningeal
arteries from patients with CAA (82.9 ± 7.5 yrs) compared to
young (45.4 ± 3.9 yrs) and elderly controls (88.3 ± 8.6 yrs).
Authors reported similar findings with our study demonstrating
significant alterations in immune response and classical
complement and extracellular matrix remodeling pathways
in arteries affected by CAA compared to young and elderly
controls. Clusterin (apolipoprotein J) and tissue inhibitor
of metalloproteinases-3 (TIMP3) were the top significantly
regulated proteins to be upregulated in CAA compared to young
and elderly controls, and they were found to co-localize with
amyloid-beta from CAA lesions. In our study, we also saw
changes in clusterins in young vs. aged cerebrovessels, and early
changes in matrix metalloproteinases such as MMP12 in CAA
pathogenesis, suggesting a role for these proteins in driving the
molecular damage in CAA pathogenesis.
Another study using laser dissection microscopy assisted
quantitative mass spectrometry analysis was used to interrogate
post-mortem human brain tissue of AD lesions with amyloid
deposits in the brain parenchyma, predominant severe capillary
CAA, and non-demented controls without amyloid deposits
(Hondius et al., 2018). The authors identified 29 CAA-
selective proteins. Notably increased levels of clusterin (CLU),
apolipoprotein E (APOE) and serum amyloid P-component
(APCS) were observed in AD brains with CAA, and collagen
alpha-2(VI) (COL6A2) as highly selective markers unique to
only CAA but absent in cases with parenchymal amyloid.
Collagen makes up 50% of basement membrane proteins, and
we also found increased levels of COL1A1 protein subunit
in AD cases with low vs. high CAA scores, suggesting that
extracellular remodeling is a key protective mechanisms against
CAA pathogenesis, to combat weakening of vascular basement
membrane integrity.
Animal studies have also been used to explore changes
to the cerebrovascular proteome in AD pathogenesis. A
prior study used gel-free and gel-based mass spectrometry
to interrogate cerebrovascular proteome in 6.5 month old
mice overexpressing APP compared to non-transgenic controls,
and demonstrated over 190 proteins significantly regulated
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TABLE 5 | List of Top 25 proteins significantly regulated in the inferior frontal gyrus cerebrovasculature of low vs. high CAA [AD] cases.
Gene name Uniprot ID Protein name Biological function Log2FC –Log10 (P
value)
LDHB Q5U077 L-lactate dehydrogenase Carbohydrate metabolic process −0.41 2.84
PKM2 A0A024R5Z9 Pyruvate kinase Glycolysis −0.39 2.66
CRYM Q14894 Ketimine reductase mu-crystallin Lysine catabolic process −0.37 2.53
VLC-ACDm B4DEA8 Very-long-chain specific
acyl-CoAdehydrogenase, mitochondrial
Fatty acid and amino acid catabolism −0.34 2.45
OGDHL Q9ULD0 2-oxoglutarate dehydrogenase-like,
mitochondrial
Degrades glucose and glutamate −0.4 2.34
ALDH5A1 V9HWE0 Succinate-semialdehyde dehydrogenase Negative regulation of coagulation 0.27 2.31
ZNF512 Q96ME7 Zinc finger protein 512 DNA and metal ion binding −0.29 2.22
MYO5A F8W6H6 Unconventional myosin-Va Transport of vesicles to the plasma
membrane
−0.4 2.22
HEL-S-34 D9IAI1 Phosphatidylethanolamine binding protein
1
Serine protease inhibitor which inhibits
thrombin
−0.42 2.19
ACTN2 P35609 Alpha-actinin-2 (Alpha-actinin skeletal
muscle isoform 2)





Canonical glycolysis −0.37 2
ESYT2 A0A087WXU3 Extended synaptotagmin-2 Lipid transport 0.57 1.97
LRRC47 Q8N1G4 Leucine-rich repeat-containing protein 47 RNA binding −0.32 1.95
DECR1 A0A024R9D7 2,4-dienoyl CoA reductase 1,
mitochondrial, isoform
Beta-oxidation enzyme −0.43 1.95
DPYSL2 A0A1C7CYX9 Dihydropyrimidinase-related protein 2 Cytoskeleton organization −0.3 1.92
GTPBP4 D2CFK9 Nucleolar GTP-binding protein 1 Maturation of LSU-rRNA from tricistronic
rRNA transcript
0.36 1.9
BM88 B2R7I3 BM88 antigen (BM88), mRNA Neuron differentiation −0.3 1.89
AP2A2 O94973 Adaptor protein complex AP-2 subunit
alpha-2
Antigen processing and presentation of
exogenous peptide antigen via MHC class
II
−0.29 1.88
CS O75390 Citrate synthase, mitochondrial Carbohydrate metabolic process −0.34 1.87
ALDOA J3KPS3 Fructose-bisphosphate aldolase Glycolytic process [GO:0006096] −0.28 1.87
MLF2 Q15773 Myeloid leukemia factor 2 Regulation of transcription,
DNA-templated
−0.34 1.87
PROSC D3DSW3 Pyridoxal phosphate homeostasis protein Intracellular homeostatic regulation of
vitamin B6
0.32 1.85
MYO1C O00159 Unconventional myosin-Ic (Myosin I beta) Actin filament organization 0.3 1.82
CKMT1A/1B P12532 Creatine kinase U-type, mitochondrial Creatine metabolic process −0.38 1.82
NDUFA9 Q16795 NADH dehydrogenase [ubiquinone] 1
alpha subcomplex subunit 9
Accessory subunit of the mitochondrial
membrane respiratory chain
−0.24 1.82
Data are expressed as the negative Log10 of the p-value (significance cut off set at >1.3 or P < 0.05), and the Log 2 fold change between low vs. high CAA [AD] cases.
(Badhwar et al., 2017). Themolecular changes identified included
changes such as RNA/DNA damage, vascular cytoskeleton
alterations, deregulation of the oxidoreductase system, oxidative
stress, alterations in cerebrovascular vasocontractile tone,
and vascular compliance, which were all in line with the
outcomes reported in our current study. Some of these
effects were rescued by treatment with pioglitazone, which
acts through nuclear hormone receptor PPARγ to regulate
lipid and glucose metabolism, mitochondrial bioenergetics, and
inflammation. In our studies alterations in TCA cycle II,
gluconeogenesis, sirtuin signaling, oxidative phosphorylation
and mitochondrial dysfunction were observed in cerebrovessels
with aging and AD pathogenesis, indicating that mitochondrial
bioenergetics is a major event implicated in cerebrovascular
dysfunction and diminished cerebral perfusion. Collectively
these findings provide evidence for targeting energy metabolism
and mitochondrial pathobiology in the cerebrovasculature
as a potential therapeutic approach in the early stages of
AD pathology.
We noted that AD cases with low or high CAA scores
consisted of 40 or 67% APOE4 allele carriers, respectively, while
only 20% of aged non-demented control cases were APOE4 allele
carriers, suggesting that APOE4 genotype may be a driver of
the events we reported in this study. APOE is thought to play a
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role in regulating the metabolism and perivascular drainage of
Aβ and other soluble metabolites in extracellular fluids of the
brain (Kim et al., 2009; Castellano et al., 2011; Cramer et al.,
2012; Verghese et al., 2013; Kanekiyo et al., 2014). Early clues
linking APOE with vascular degeneration was demonstrated in
studies showing a link between APOE4 and increased toxic
amyloid deposition around blood vessels in CAA (Greenberg
et al., 1995; McCarron and Nicoll, 2000; Nelson et al., 2013;
Rannikmäe et al., 2014). This has now been corroborated in
transgenic models where an isoform specific (E4>E2 and/or
E3) shift in Aβ from the brain parenchyma to arterioles was
observed in the form of CAA and increased incidence of
microhemorrhages (Greenberg et al., 1995; Holtzman et al., 2000;
Fryer et al., 2003, 2005; Sullivan et al., 2008; Tai et al., 2011).
APOE4 has also been shown to impact BBB permeability at
the level of endothelial cells as demonstrated by an isoform
specific (E4>E3) increase in the mRNA levels of influx Aβ
transporters, RAGE (by seven-fold) (Donahue and Johanson,
2008). The APOE4 isoform has also been shown to negatively
impact MMP9 induced (efflux transporter) LRP-1 shedding and
its subsequent transport of APOE-Aβ complexes (Alonzo et al.,
1998). Reductions in LRP1 levels were observed in this study,
in corroboration with our previous work using the same batch
of control and AD cerbrovessel samples and ELISA analyses
(Alonzo et al., 1998).
Other studies have implicated a role for APOE4 in non-
amyloidogenic mechanisms involving direct damage to the
vasculature in AD. For example, a significant correlation between
APOE4 allele and cerebral small-vascular diseases (CSVD) has
been reported in cross-sectional studies involving AD and age-
matched control cases (Utter et al., 2008; Schilling et al., 2013;
Luo et al., 2017). APOE4 has also been linked with increased risk
for fat or cholesterol build up in the middle cerebral artery in
elderly patients (Kosunen et al., 1995; Zhang et al., 2018), and
could lead to stenosis and the decrease in cerebral perfusion by
smaller penetrating blood vessels. Moreover, CAA patients in the
amyloid antibody trials who are APOE4 carriers typically show
an increased propensity for microhemorrhages (Roher et al.,
2011; Hanson et al., 2014; Salloway et al., 2014). Recent work
has also confirmed the link between APOE4 and the accelerated
breakdown of the BBB as an early event in AD (Zipser et al.,
2007; Dickstein et al., 2010; Bell et al., 2012; Montagne et al.,
2020). This appears to be driven by an APOE4 effect on the LRP1-
Cyclophilin-NF-κB-MMP9 pathway in pericytes (Bell et al., 2012;
Halliday et al., 2016; Montagne et al., 2020). Damage to mural
cells could impact on the vasoconstrictive properties of cerebral
microvessels leading to diminished blood flow and impaired
cerebrovascular clearance (Hamilton, 2010; Khennouf et al.,
2018; Nortley et al., 2019). While damage to the BBB can result
in leukocyte extravasation and influx of blood borne proteins
(such as fibrinogen and ferritin), which were both observed in
this current study between control and AD cases.
One of the limitations of our study is the inability to
detect the specific cellular origins of all the differentially
expressed proteins in the cerebrovasculature, which constitutes
a mixed cell population. Therefore, in future studies, we
propose interrogating these omic changes at the single cell
level using tools such as single cell RNAseq, RNAscope, single
cell proteomic analyses and double-immunofluorescent staining.
Another limitation of this work, is the bias in gender distribution
across the different groups, with more females in the AD cases
(60-70%) compared to the controls (∼40%). Moreover, our
young healthy control cohort coincidentally consisted of 60%
APOE4 allele carriers, while the aged-matched control cases
consisted of 20%. Thus our findings must be interpreted based
on the bias across these groups as sex may serve as a biological
variable driving our outcomes, while APOE4 genotype in the
young cases may also mask some of the age-related effects
observed in the study.
Conclusion
We hypothesized that age-related and CAA dependent changes
to the cerebrovascular proteome may explain the vascular
contribution of aging and CAA in AD-related pathogenesis.
We have observed that chemokine signaling, neurovascular
signaling, hypoxia and oxidative damage and cell to cell signaling
pathways were some of the prominent features of early age-
related changes to cerebrovessels and this was driven by upstream
regulators such as pro-survival and growth factor regulator
RICTOR, transcriptional co-repressor TLE3, tau gene MAPT,
amyloid precursor protein APP, and amyloidolytic enzyme
subunit PSEN1.
We also revealed that proteomic changes to cerebrovessels
across the neuropathological staging of CAA in AD brains
appeared to be influenced early on by changes in energy
bioenergetic, cellular homeostasis, BBB disturbances and
immune cell infiltration. This was found to be driven by
upstream regulators such as matrix metalloproteinase enzyme
MMP12, endopeptidase enzyme CLPP, RICTOR and TLE3. The
most common denominator in AD cerebrovessels from this study
is the failure of mitochondrial function and energy bioenergetics.
We hypothesize that mitochondrial failure in cerebrovessels
may be a novel target in AD pathogenesis, and thus serve as
a potential therapeutic target for rejuvenating cerebrovascular
function and mitigating its negative consequences in AD.
It is worthy of note that low CAA groups represented cases
with 50% high “NIA-R” AD diagnosis; while high CAA groups
represented cases with 90%, suggesting that the effects observed
are not absolutely driven by CAA score, but can be influenced
by advanced amyloid plaque and NFT stage. Future studies
exploring the differences in low and high CAA cases within
a population with high NIA-R or ADNC diagnosis may help
to determine the proteomic changes attributed primarily to
CAA severity.
The findings nonetheless have provided a valuable molecular
library of cerebrovascular pathobiological changes in aging
and AD pathogenesis. The cerebrovasculature is crucial
for maintaining neurovascular coupling and homeostatic
equilibrium of the brain, providing adequate oxygen and
glucose supply to cells to carry out their normal physiological
functions. The proteomic changes we have identified may
provide novel cerebrovascular based targets in developing
therapeutic strategies to mitigate the damage to cerebrovessels
early in the sequelae of AD pathogenesis. Our findings may
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also provide markers to aid in stratifying CAA patients during
clinical trial studies for anti-amyloid immunotherapies that have
an increased risk for microhemorrhages (Racke et al., 2005;
Wilcock and Colton, 2009; Wilcock et al., 2011). Our future
work will focus on interrogating and validating these novel
targets and pathways and their functional significance in a larger
cohorts of human samples and in controlled preclinical and
in vitro studies.
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Supplementary Figure 1 | Network functions identified in young vs. aged control
cerebrovascular tissue from the inferior frontal gyrus. Top Table shows associated
network functions score identified from the ingenuity pathway analyses of
significantly regulated proteins in young vs. aged controls. Network score was
generated using IPA network generation algorithm that calculates the probability of
finding the significantly regulated focus genes in a set of genes randomly selected
from the relevant global molecular network. Network score cut off was set at >40.
Schematic representation shows subcellular localization of proteins from each
identified networks. Red—downregulated and Green—upregulated.
Supplementary Figure 2 | Network functions identified in low CAA vs.
aged-matched control cerebrovascular tissue from the inferior frontal gyrus. Top
Table shows associated network functions score identified from the ingenuity
pathway analyses of significantly regulated proteins in low CAA vs. aged-matched
control cases. Network score was generated using IPA network generation
algorithm that calculates the probability of finding the significantly regulated focus
genes in a set of genes randomly selected from the relevant global molecular
network. Network score cut off was set at >40. Schematic representation shows
subcellular localization of proteins from each identified networks.
Red—downregulated and Green—upregulated.
Supplementary Figure 3 | Network functions identified in high CAA vs.
aged-matched control cerebrovascular tissue from the inferior frontal gyrus. Top
Table shows associated network functions score identified from the ingenuity
pathway analyses of significantly regulated proteins in high CAA vs.
aged-matched control cases. Network score was generated using IPA network
generation algorithm that calculates the probability of finding the significantly
regulated focus genes in a set of genes randomly selected from the relevant global
molecular network. Network score cut off was set at >40. Schematic
representation shows subcellular localization of proteins from each identified
networks. Red—downregulated and Green—upregulated.
Supplementary Figure 4 | Network functions identified in low vs. high CAA[AD]
cerebrovascular tissue from the inferior frontal gyrus. Top Table shows associated
network functions score identified from the ingenuity pathway analyses of
significantly regulated proteins in low vs. high CAA [AD] cases. Network score was
generated using IPA network generation algorithm that calculates the probability of
finding the significantly regulated focus genes in a set of genes randomly selected
from the relevant global molecular network. Network score cut off was set at >40.
Schematic representation shows subcellular localization of proteins from each
identified networks. Red—downregulated and Green—upregulated.
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Supplementary Table 1 | List of significantly regulated proteins in the
cerebrovasculature of the inferior frontal gyrus of young vs. aged control cases.
Data are expressed as the negative Log10 of the p-value (green horizontal
bars–significance cut off set at >1.3), and the Log2 fold change between young
vs. aged control cases. Heat map indicates downregulated (Red box) or
upregulated (Blue box) proteins. Statistical analyses was performed using t-test
after logarithmic transformation. Red text highlights indicate 124 significantly
proteins identified that were unique to only this comparison in our entire study.
Supplementary Table 2 | List of significantly regulated proteins in the
cerebrovasculature of the inferior frontal gyrus of low CAA+ Alzheimer’s disease
and aged-matched control cases. Data are expressed as the negative Log10 of
the p-value (green horizontal bars–significance cut off set at >1.3), and the Log2
fold change between low CAA [AD] vs. age-matched control cases. Heat map
indicates downregulated (Red box) or upregulated (Blue box) proteins. Statistical
analyses was performed using t-test after logarithmic transformation. Red text
highlights indicate 17 significantly proteins identified that were unique to only this
comparison in our entire study.
Supplementary Table 3 | List of significantly regulated proteins in the
cerebrovasculature of the inferior frontal gyrus in high CAA [AD] vs. age-matched
control cases. Data are expressed as the negative Log10 of the p-value (green
horizontal bars–significance cut off set at >1.3), and the Log2 fold change
between high CAA [AD] vs. age-matched control cases. Heat map indicates
downregulated (Red box) or upregulated (Blue box) proteins. Statistical analyses
was performed using t-test after logarithmic transformation. Red text highlights
indicate 155 significantly proteins identified that were unique to only this
comparison in our entire study.
Supplementary Table 4 | List of significantly regulated proteins in the
cerebrovasculature of the inferior frontal gyrus in low vs. high CAA [AD] cases.
Data are expressed as the negative Log10 of the p value (green horizontal
bars–significance cut off set at >1.3), and the Log2 fold change between low vs.
high CAA [AD] cases. Heat map indicates downregulated (Red box) or
upregulated (Blue box) proteins. Statistical analyses was performed using t-test
after logarithmic transformation. Red text highlights indicate 36 significantly
proteins identified that were unique to only this comparison in our entire study.
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